Is PT-141 (Bremelanotide) Legal in Wisconsin? How to Access It Legally
HealthRX.com
Vyleesi is the FDA-approved prescription form of bremelanotide
See the public record for Bremelanotide
At a glance
- FDA status / Approved as Vyleesi, NDA 210557, June 21, 2019 [1][2]
- Form / 1.75 mg subcutaneous autoinjector, prescription only [1]
- Approved use / Acquired, generalized HSDD in premenopausal women [1]
- Not indicated for / Men, postmenopausal women, or enhancing sexual performance [1]
- Boxed warning and REMS / Neither appears in the label or the 2019 approval letter [1][2]
What PT-141 is, for legal purposes
Bremelanotide is a cyclic peptide of seven amino acids and a melanocortin receptor agonist [1]. FDA approved it on June 21, 2019, as Vyleesi under NDA 210557; the current holder is Cosette Pharmaceuticals [1][2]. It is a 1.75 mg subcutaneous injection in a prefilled autoinjector, prescription only [1].
The approved use is premenopausal women with acquired, generalized hypoactive sexual desire disorder. The label says Vyleesi is not indicated for postmenopausal women or in men, and not to enhance sexual performance [1]. It has no boxed warning, and no REMS appears in the label or in the 2019 approval letter [1][2].
Compounded and research-use PT-141
Compounded PT-141 products are not FDA-approved drugs, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing [3]. Research-use PT-141 products are likewise not FDA-approved drugs [1][3].
Bremelanotide is not on FDA's page of bulk substances that may raise significant safety risks when compounded, content dated April 22, 2026 [4], and it is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [5].
Does Wisconsin add anything?
This page does not establish a Wisconsin-specific rule for bremelanotide. The federal position is that Vyleesi is the approved prescription product [1][2].
Questions worth asking
What the prescribing information says about use
The label lists uncontrolled hypertension and known cardiovascular disease as contraindications and says Vyleesi is not recommended for people at high cardiovascular risk. It describes assessing cardiovascular risk and making sure blood pressure is well controlled before and during treatment [1]. It also says to use effective contraception and to discontinue Vyleesi if pregnancy is suspected [1].
The label says to avoid Vyleesi with oral naltrexone-containing products intended to treat alcohol or opioid addiction, because of the severe consequence of naltrexone treatment failure [1]. It also says Vyleesi may slow stomach emptying and reduce absorption of oral medicines, and to avoid it with oral drugs that depend on threshold concentrations for efficacy, such as antibiotics [1].
For dosing, the label lists 1.75 mg under the skin of the abdomen or thigh as needed, at least 45 minutes before anticipated sexual activity, no more than one dose in 24 hours, and no more than 8 doses a month. It says to stop after 8 weeks if there is no improvement in symptoms [1].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Is PT-141 the same as Vyleesi?
Does Wisconsin have its own rule on PT-141?
Who is Vyleesi approved for?
Does Vyleesi have a boxed warning or REMS?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
How long does it take for PT-141 peptide to kick in?
The label says to inject 1.75 mg under the skin of the abdomen or thigh at least 45 minutes before anticipated sexual activity. No more than one dose is allowed in 24 hours and no more than 8 doses a month. If symptoms do not improve, the label says to stop after 8 weeks.
What are good legitimate sources for PT-141 in the US?
Vyleesi, the FDA-approved bremelanotide product, is the approved prescription option. It is a 1.75 mg prefilled autoinjector sold by prescription only. Compounded and research-use PT-141 products are not FDA-approved drugs, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing.
References
Show all 5 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration. Approval letter, NDA 210557 (Vyleesi), 2019. FDA approval letter, NDA 210557
- Federal Register. Public inspection document 2026-22192, 2026. Federal Register public inspection document 2026-22192
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA
- U.S. Department of Health and Human Services. 503A peptide enforcement discretion policy, Appendix B, 2026. HHS peptide enforcement-discretion policy, Appendix B